P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness

被引:26
|
作者
Thuault, S. [1 ,2 ]
Hayashi, S. [3 ]
Lagirand-Cantaloube, J. [1 ,2 ]
Plutoni, C. [1 ,2 ]
Comunale, F. [1 ,2 ]
Delattre, O. [4 ]
Relaix, F. [3 ]
Gauthier-Rouviere, C. [1 ,2 ]
机构
[1] Univ Montpellier 2, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[2] Univ Montpellier I, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[3] INSERM UPMC AIM, UMRS787, Paris, France
[4] Inst Curie, INSERM Unite 830, Unite Genet Somat, Paris, France
关键词
P-cadherin; rhabdomyosarcoma; PAX3-FOXO1A; invasion; cadherin switch; TRANSCRIPTIONAL ACTIVATOR; SKELETAL MYOGENESIS; CELL-MIGRATION; GENE FUSIONS; PAX GENES; EXPRESSION; PAX3-FKHR; IDENTIFICATION; FAMILY; TRANSFORMATION;
D O I
10.1038/onc.2012.217
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS. Oncogene (2013) 32, 1876-1887; doi:10.1038/onc.2012.217; published online 18 June 2012
引用
收藏
页码:1876 / 1887
页数:12
相关论文
共 50 条
  • [21] Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells
    Calhabeu, F.
    Hayashi, S.
    Morgan, J. E.
    Relaix, F.
    Zammit, P. S.
    ONCOGENE, 2013, 32 (05) : 651 - 662
  • [22] FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma
    Milewski, David
    Shukla, Samriddhi
    Gryder, Berkley E.
    Pradhan, Arun
    Donovan, Johnny
    Sudha, Parvathi
    Vallabh, Sushmitha
    Pyros, Athena
    Xu, Yan
    Barski, Artem
    Szabo, Sara
    Turpin, Brian
    Pressey, Joseph G.
    Millay, Douglas P.
    Khan, Javed
    Kalinichenko, Vladimir V.
    Kalin, Tanya, V
    ONCOGENE, 2021, 40 (12) : 2182 - 2199
  • [23] Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells
    Liu, Lingling
    Wu, Jing
    Ong, Su Sien
    Chen, Taosheng
    PLOS ONE, 2013, 8 (02):
  • [24] PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis
    Kendall, Genevieve C.
    Watson, Sarah
    Xu, Lin
    LaVigne, Collette A.
    Murchison, Whitney
    Rakheja, Dinesh
    Skapek, Stephen X.
    Tirode, Franck
    Delattre, Olivier
    Amatruda, James F.
    ELIFE, 2018, 7
  • [25] PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features
    Raze, Thomas
    Lapouble, Eve
    Lacour, Brigitte
    Guissou, Sandra
    Defachelles, Anne-Sophie
    Gaspar, Nathalie
    Delattre, Olivier
    Pierron, Gaelle
    Desandes, Emmanuel
    PEDIATRIC BLOOD & CANCER, 2023, 70 (04)
  • [26] PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma
    Hanna, Jason A.
    Garcia, Matthew R.
    Lardennois, Alicia
    Leavey, Patrick J.
    Maglic, Dino
    Fagnan, Alexandre
    Go, Jonathan C.
    Roach, Jordan
    Wang, Yong-Dong
    Finkelstein, David
    Hatley, Mark E.
    ONCOGENE, 2018, 37 (15) : 1991 - 2007
  • [27] PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
    Searcy, Madeline B.
    Larsen, Randolph K.
    Stevens, Bradley T.
    Zhang, Yang
    Jin, Hongjian
    Drummond, Catherine J.
    Langdon, Casey G.
    Gadek, Katherine E.
    Vuong, Kyna
    Reed, Kristin B.
    Garcia, Matthew R.
    Xu, Beisi
    Kimbrough, Darden W.
    Adkins, Grace E.
    Djekidel, Nadhir
    Porter, Shaina N.
    Schreiner, Patrick A.
    Pruett-Miller, Shondra M.
    Abraham, Brian J.
    Rehg, Jerold E.
    Hatley, Mark E.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [28] Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma
    Jothi, Mathivanan
    Mal, Munmun
    Keller, Charles
    Mal, Asoke K.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (12) : 2663 - 2674
  • [29] Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma
    Kanayama, Takuyo
    Miyachi, Mitsuru
    Sugimoto, Yohei
    Yagyu, Shigeki
    Kikuchi, Ken
    Tsuchiya, Kunihiko
    Iehara, Tomoko
    Hosoi, Hajime
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [30] Early detection of the PAX3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma
    Eguchi-Ishimae, Minenori
    Tezuka, Mari
    Kokeguchi, Tomoki
    Nagai, Kozo
    Moritani, Kyoko
    Yonezawa, Sachiko
    Tauchi, Hisamichi
    Tokuda, Kiriko
    Ishida, Yasushi
    Ishii, Eiichi
    Eguchi, Mariko
    GENES CHROMOSOMES & CANCER, 2019, 58 (08): : 521 - 529